<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">ACM</journal-id><journal-title-group><journal-title>Advances in Clinical Medicine</journal-title></journal-title-group><issn pub-type="epub">2161-8712</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/ACM.2019.98137</article-id><article-id pub-id-type="publisher-id">ACM-31582</article-id><article-categories><subj-group subj-group-type="heading"><subject>ACM20190800000_40301773.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  国内外川崎病临床治疗进展
  Progress in Clinical Treatment of Kawasaki Disease at Home and Abroad
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>吕</surname><given-names>菊红</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>马</surname><given-names>红茹</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>邓</surname><given-names>峰</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff2"><addr-line>陕西省宝鸡市中心医院儿科，陕西 宝鸡</addr-line></aff><aff id="aff3"><addr-line>陕西省宝鸡市疾病预防控制中心，陕西 宝鸡</addr-line></aff><aff id="aff1"><addr-line>null</addr-line></aff><pub-date pub-type="epub"><day>05</day><month>08</month><year>2019</year></pub-date><volume>09</volume><issue>08</issue><fpage>889</fpage><lpage>897</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  
    疾病的临床治疗方法是否科学、有效，根本上有赖于对疾病的发病机制或病因的研究清晰程度。尽管自从全球首个川崎病研究报道至今已过去了半个多世纪，但其发病机制或病因至今尚未研究清楚。虽然目前国内外川崎病的临床治疗仍以药物对症处理为主，但国外临床治疗与研究进展相对较快。在我国川崎病发病呈逐年上升的背景下，有必要及时对国内外川崎病临床治疗与研究进展进行综述，以便为提高我国川崎病临床治疗水平提供参考。
    Whether the clinical treatment of diseases is scientific and effective depends on the clarity of the pathogenesis or etiology of the disease. Although more than half a century has passed since the world’s first Kawasaki disease research report, its etiology has not yet been studied. Although the clinical treatment of Kawasaki disease at home and abroad is still based on drug symptomatic treatment, the progress of clinical treatment and research abroad is relatively fast. Under the in-creasing trend of Kawasaki disease in China, it is necessary to review the progress of clinical treatment and research of Kawasaki disease at home and abroad in order to provide a reference for improving the clinical treatment level of Kawasaki disease in China. 
  
 
</p></abstract><kwd-group><kwd>川崎病，临床治疗，国际, Kawasaki Disease</kwd><kwd> Clinical Treatment</kwd><kwd> International</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>国内外川崎病临床治疗进展<sup> </sup></title><p>吕菊红<sup>1,2*</sup>，马红茹<sup>1,2</sup>，邓峰<sup>3,4#</sup></p><p><sup>1</sup>陕西省宝鸡市中心医院儿科，陕西 宝鸡</p><p><sup>2</sup>西安交通大学附属宝鸡市中心医院儿科，陕西 宝鸡</p><p><sup>3</sup>陕西省宝鸡市疾病预防控制中心，陕西 宝鸡</p><p><sup>4</sup>西安交通大学宝鸡预防医学研究院，陕西 宝鸡</p><p><img src="//html.hanspub.org/file/1-1570964x1_hanspub.png" /></p><p>收稿日期：2019年7月11日；录用日期：2019年7月29日；发布日期：2019年8月5日</p><disp-formula id="hanspub.31582-formula4"><graphic xlink:href="//html.hanspub.org/file/1-1570964x6_hanspub.png"  xlink:type="simple"/></disp-formula></sec><sec id="s2"><title>摘 要</title><p>疾病的临床治疗方法是否科学、有效，根本上有赖于对疾病的发病机制或病因的研究清晰程度。尽管自从全球首个川崎病研究报道至今已过去了半个多世纪，但其发病机制或病因至今尚未研究清楚。虽然目前国内外川崎病的临床治疗仍以药物对症处理为主，但国外临床治疗与研究进展相对较快。在我国川崎病发病呈逐年上升的背景下，有必要及时对国内外川崎病临床治疗与研究进展进行综述，以便为提高我国川崎病临床治疗水平提供参考。</p><p>关键词 :川崎病，临床治疗，国际</p><disp-formula id="hanspub.31582-formula5"><graphic xlink:href="//html.hanspub.org/file/1-1570964x7_hanspub.png"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2019 by author(s) and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/1-1570964x8_hanspub.png" /> <img src="//html.hanspub.org/file/1-1570964x9_hanspub.png" /></p></sec><sec id="s3"><title>1. 引言</title><p>川崎病(Kawasaki disease, KD)是一种病因不明的急性发热性多系统性血管炎 [<xref ref-type="bibr" rid="hanspub.31582-ref1">1</xref>] 。在全球范围内，KD是最常见的原发性儿童血管炎，被认为是迄今为止发达国家儿童最常见的获得性心脏病 [<xref ref-type="bibr" rid="hanspub.31582-ref2">2</xref>] 。既往流行病学调查结果显示，我国KD发病有逐年增多趋势 [<xref ref-type="bibr" rid="hanspub.31582-ref3">3</xref>] [<xref ref-type="bibr" rid="hanspub.31582-ref4">4</xref>] 。近年来，国外有关KD的临床治疗与研究最新报道不断出现，值得深入学习与研究，以便更好地为我国KD临床治疗提供借鉴。</p></sec><sec id="s4"><title>2. 国外KD临床治疗进展</title><p>尽管自从全球首个KD报道至今，已过去了半个多世纪，但其发病机制或病因至今尚未研究清楚 [<xref ref-type="bibr" rid="hanspub.31582-ref5">5</xref>] 。目前，国外KD的临床治疗仍以药物对症处理为主。</p><sec id="s4_1"><title>2.1. 急性期KD治疗</title><sec id="s4_1_1"><title>2.1.1. 静脉注射免疫球蛋白(Intravenous immunoglobulin, IVIG)</title><p>使用IVIG治疗KD对控制炎症至关重要 [<xref ref-type="bibr" rid="hanspub.31582-ref6">6</xref>] 。IVIG治疗KD第一个文献报道可追溯到1980年代Furusho等 [<xref ref-type="bibr" rid="hanspub.31582-ref7">7</xref>] 。从那时起，IVIG已成功用于治疗许多KD病例。按照美国儿科学会(American academy of pediatrics, AAP)和美国心脏协会(American heart association, AHA) KD诊疗指南，在KD症状出现后10天内开始按12小时内单次剂量2 g/kg输注IVIG治疗，可以看到最好的治疗效果 [<xref ref-type="bibr" rid="hanspub.31582-ref2">2</xref>] 。在症状出现后10天IVIG治疗患者的疗效尚不明确，建议尽快开始IVIG治疗 [<xref ref-type="bibr" rid="hanspub.31582-ref8">8</xref>] 。但是，如果患者出现持续发热或其他炎症迹象，仍建议对晚于10天的患者进行IVIG治疗 [<xref ref-type="bibr" rid="hanspub.31582-ref9">9</xref>] 。但有研究认为，在发烧第5天之前给予IVIG治疗可能会无意中增加对进一步IVIG治疗的需求，并且还会增加发生难治性状态的机会 [<xref ref-type="bibr" rid="hanspub.31582-ref10">10</xref>] 。</p></sec><sec id="s4_1_2"><title>2.1.2. 阿司匹林(Aspirin, ASA)</title><p>ASA与IVIG一起用于KD急性期治疗，其剂量因国家不同而异 [<xref ref-type="bibr" rid="hanspub.31582-ref11">11</xref>] [<xref ref-type="bibr" rid="hanspub.31582-ref12">12</xref>] 。美国推荐剂量为80~100 mg/kg/d，日本考虑到ASA对肝脏的损害，建议为30~50 mg/kg/d [<xref ref-type="bibr" rid="hanspub.31582-ref12">12</xref>] [<xref ref-type="bibr" rid="hanspub.31582-ref13">13</xref>] 。有研究发现，上述两种治疗方案的疗效相似 [<xref ref-type="bibr" rid="hanspub.31582-ref14">14</xref>] 。有关ASA的治疗持续时间尚有争议 [<xref ref-type="bibr" rid="hanspub.31582-ref15">15</xref>] [<xref ref-type="bibr" rid="hanspub.31582-ref16">16</xref>] 。有研究倾向于将ASA治疗持续2周而不考虑发烧状态，然后转为低剂量(3~5 mg/kg/d)，如果随访超声心动图检查正常，然后将该低剂量持续6~8周并停止 [<xref ref-type="bibr" rid="hanspub.31582-ref17">17</xref>] 。根据AHA建议，在急性期，患者给予80~100 mg/kg/d，分4次给药，然后在KD亚急性期至少6~8天给予3~5 mg/kg/d；如果患者出现冠状动脉异常，则以低剂量继续服用，直至出现冠状动脉异常(coronary artery anomalies, CAA)消退的超声心动图证据，如果有CAA证据，则持续用药 [<xref ref-type="bibr" rid="hanspub.31582-ref2">2</xref>] 。</p></sec><sec id="s4_1_3"><title>2.1.3. 皮质类固醇(Corticosteroids, CCs)</title><p>1979年Kato等报道称，在KD急性期给予CCs治疗可导致CAA发病率增加 [<xref ref-type="bibr" rid="hanspub.31582-ref18">18</xref>] ，从此对KD急性期使用CCs慎之又慎。但后来的研究发现，这些结果是由于给予CCs治疗组的患儿比对照组患儿病情更重的混杂因素引起 [<xref ref-type="bibr" rid="hanspub.31582-ref19">19</xref>] ，可见研究设计是否科学有多么重要。Kobayashi等研究结果显示，CCs可能在KD急性期有用 [<xref ref-type="bibr" rid="hanspub.31582-ref20">20</xref>] 。AHA指南不支持在KD急性期初次IVIG治疗的同时给予甲基强的松龙脉冲，但建议2-3周后使用CCs治疗可能会对IVIG和ASA的使用剂量减少有益 [<xref ref-type="bibr" rid="hanspub.31582-ref2">2</xref>] 。前期CCs治疗可能仅适用于已被证实具有IVIG耐药性或具有明显CAA患者 [<xref ref-type="bibr" rid="hanspub.31582-ref21">21</xref>] [<xref ref-type="bibr" rid="hanspub.31582-ref22">22</xref>] 。CCs的选择通常是静脉注射甲基强的松龙脉冲，然后口服强的松龙逐渐减少剂量 [<xref ref-type="bibr" rid="hanspub.31582-ref2">2</xref>] 。</p></sec></sec><sec id="s4_2"><title>2.2. 耐药性KD治疗</title><p>美国AHA和AAP将耐药性KD定义为经IVIG初次治疗仍发热超过36 h或以上，或再度发热患者 [<xref ref-type="bibr" rid="hanspub.31582-ref2">2</xref>] 。</p><sec id="s4_2_1"><title>2.2.1. CCs</title><p>有研究表明，CCs联合IVIG和ASA治疗KD可降低患者CAA风险 [<xref ref-type="bibr" rid="hanspub.31582-ref23">23</xref>] 。日本大规模随机对照试验结果显示，对KD患者给予IVIG加泼尼松龙治疗后冠状动脉病变得到改善 [<xref ref-type="bibr" rid="hanspub.31582-ref20">20</xref>] 。使用静脉注射甲基强的松龙，单次剂量为30 mg/kg，每日2~3次，连续2~3天是最常用的CCs治疗方案 [<xref ref-type="bibr" rid="hanspub.31582-ref24">24</xref>] 。但是，关于在KD中使用CCs的适应症仍存争议。有人建议仅在对2次以上输注IVIG无反应的病例中使用CCs，而其他人建议在第1次IVIG治疗不能降低炎症的情况下使用CCs [<xref ref-type="bibr" rid="hanspub.31582-ref24">24</xref>] 。AHA建议对2次输注IVIG未能做出反应的患者使用CCs [<xref ref-type="bibr" rid="hanspub.31582-ref2">2</xref>] 。诸多研究表明，联合甲基强的松龙和IVIG治疗难治性KD患者的预后较好，且有助于降低CAA风险 [<xref ref-type="bibr" rid="hanspub.31582-ref25">25</xref>] [<xref ref-type="bibr" rid="hanspub.31582-ref26">26</xref>] [<xref ref-type="bibr" rid="hanspub.31582-ref27">27</xref>] 。有研究发现，与接受第2剂次IVIG治疗患者相比，甲基强的松龙治疗患者的窦性心动过缓和高血糖发生率更高，虽然这些不良反应只是短暂的，但表明需要对CCs治疗的患者进行监测 [<xref ref-type="bibr" rid="hanspub.31582-ref28">28</xref>] 。Lim等研究表明，联合使用地塞米松和高剂量IVIG的临床疗效较好，发热期较短，IVIG第2次剂量需求较少，住院时间缩短而心血管预后不会恶化 [<xref ref-type="bibr" rid="hanspub.31582-ref29">29</xref>] 。</p></sec><sec id="s4_2_2"><title>2.2.2. TNF-α抑制剂(TNF-α inhibitors)</title><p>TNF-α拮抗剂可分为两类：单克隆抗体(英夫利昔单抗和阿达木单抗)和可溶性受体(依那西普) [<xref ref-type="bibr" rid="hanspub.31582-ref30">30</xref>] 。英夫利昔单抗是一种嵌合单克隆抗体，已有许多研究报道可用于治疗难治性KD [<xref ref-type="bibr" rid="hanspub.31582-ref31">31</xref>] 。Mori等对IVIG难治的患者进行了英夫利昔单抗的开放性标记试验，20名患者中的18名成功用英夫利昔单抗治疗，没有任何不良反应 [<xref ref-type="bibr" rid="hanspub.31582-ref32">32</xref>] 。Tremoulet等研究表明，英夫利昔单抗有助于减少发热，降低炎症标志物和IVIG反应率，英夫利昔单抗被认为是安全且耐受良好 [<xref ref-type="bibr" rid="hanspub.31582-ref33">33</xref>] 。英夫利昔单抗通常以5 mg/kg剂量给药，且在治疗后24小时内可观察到效果 [<xref ref-type="bibr" rid="hanspub.31582-ref8">8</xref>] 。阿昔单抗是一种针对GpIIb-IIIa受体的单克隆抗体，已被用于治疗冠状动脉瘤的急性和亚急性KD病例，在标准治疗中加入阿昔单抗可使动脉瘤直径减小更多，且阿昔单抗有助于促进血管重塑，从而降低CAA风险 [<xref ref-type="bibr" rid="hanspub.31582-ref34">34</xref>] 。目前，依那西普也已被用作IVIG的辅助治疗药物，正在开展临床试验 [<xref ref-type="bibr" rid="hanspub.31582-ref35">35</xref>] 。</p></sec><sec id="s4_2_3"><title>2.2.3. 血浆置换(Plasma exchange, PE)</title><p>有研究对46名第2次静脉注射IVIG治疗无效儿童采用PE方法治疗，结果发现早期采用PE治疗有助于降低这些患者CAA发生风险 [<xref ref-type="bibr" rid="hanspub.31582-ref36">36</xref>] 。目前，效果相似的报道较多 [<xref ref-type="bibr" rid="hanspub.31582-ref12">12</xref>] [<xref ref-type="bibr" rid="hanspub.31582-ref37">37</xref>] 。PE的持续时间取决于许多因素，包括发烧症状的缓解和炎症标志物的正常化，尽管Fujimaro等人发现PE持续4~5天有效，但一般建议PE持续3~4天 [<xref ref-type="bibr" rid="hanspub.31582-ref12">12</xref>] 。Sonoda等选择了76名对2剂次IVIG无反应的KD患者，首先用英夫利昔单抗治疗，然后对那些对英夫利昔单抗无反应的患者进行PE治疗，结果炎症消退、伴随着发烧消失和实验室指标改善 [<xref ref-type="bibr" rid="hanspub.31582-ref38">38</xref>] 。基于这些发现，这些研究者得出结论，这种针对难治性KD患者的逐步治疗方案是非常有效的。</p></sec><sec id="s4_2_4"><title>2.2.4. 环孢菌素(Cyclosporine)</title><p>环孢菌素是一种钙调神经磷酸酶抑制剂 [<xref ref-type="bibr" rid="hanspub.31582-ref39">39</xref>] ，会阻断IL-2释放，IL-2是一种细胞因子信号分子 [<xref ref-type="bibr" rid="hanspub.31582-ref24">24</xref>] 。关于环孢菌素在KD治疗中的功效，存在相互矛盾的结果。Kuijpers等报道，使用环孢菌素治疗的一名16个月大的难治性KD患儿的临床结果没有改善 [<xref ref-type="bibr" rid="hanspub.31582-ref40">40</xref>] 。Suzuki等证明环孢菌素对难治性KD患者是一种安全且有前景的治疗选择，他们在日本进行了一项前瞻性病例系列研究，并报告了24例患者中有18例口服环孢菌素4~8 mg/kg/d的IVIG耐药病例 [<xref ref-type="bibr" rid="hanspub.31582-ref41">41</xref>] 。日本正在进行一项在严重KD中使用IVIG和环孢菌素的III期临床试验，患者随机接受口服环孢菌素(5 mg/kg/d，连续5天)和高剂量IVIG (2 g/kg，24小时)加ASA 30 mg/kg/d [<xref ref-type="bibr" rid="hanspub.31582-ref42">42</xref>] 。但是，环孢菌素可能对内皮有毒，因此不应常规给药，但在某些情况下可被视为潜在的治疗选择 [<xref ref-type="bibr" rid="hanspub.31582-ref43">43</xref>] ，需要进一步研究以确定环孢菌素在KD中的最佳剂量、安全性和有效性 [<xref ref-type="bibr" rid="hanspub.31582-ref8">8</xref>] 。</p></sec><sec id="s4_2_5"><title>2.2.5. 环磷酰胺(Cyclophosphamide)</title><p>环磷酰胺是一种免疫抑制药物，它抑制DNA合成和DNA链的交联，从而阻止细胞分裂，被认为可以减少KD炎症 [<xref ref-type="bibr" rid="hanspub.31582-ref44">44</xref>] 。关于KD中环磷酰胺的使用，没有很多研究。Wallace等对KD患儿的治疗进行了回顾性分析，在该研究65名儿童中，即使在2次IVIG治疗后仍有5名儿童患有持续性KD，其中4例用脉冲甲基强的松龙(30 mg/kg/d)治疗，2例用环磷酰胺(2 mg/kg/d)治疗，这些患者没有任何冠状动脉瘤或死亡进展，没有发现环磷酰胺的副作用 [<xref ref-type="bibr" rid="hanspub.31582-ref45">45</xref>] 。</p></sec><sec id="s4_2_6"><title>2.2.6. 甲氨蝶呤(Methotrexate)</title><p>甲氨蝶呤主要用作抗癌治疗，它是一种抗代谢药物，可抑制DNA合成和复制所需的二氢叶酸还原酶 [<xref ref-type="bibr" rid="hanspub.31582-ref46">46</xref>] 。在KD中，甲氨蝶呤被认为可降低C-反应蛋白(CRP)，红细胞沉降率(ESR)，并阻断IL-1和IL-6的释放 [<xref ref-type="bibr" rid="hanspub.31582-ref47">47</xref>] 。Lee等首次报道了甲氨蝶呤在一名患有难治性KD的6岁儿童中的成功应用，这名儿童对IVIG多个疗程没有反应，后来在患病的第38天开始使用甲氨蝶呤(10 mg/体表面积，每周一次)和地塞米松(每天0.6 mg/kg)，最终炎症逐渐消退 [<xref ref-type="bibr" rid="hanspub.31582-ref48">48</xref>] 。Lee等后来对17名初次IVIG治疗难以治疗的患者进行了一项前瞻性研究，然后用甲氨蝶呤(10 mg/体表面积，每周一次)治疗这些患者直至CRP值标准化，发现在用甲氨蝶呤治疗的第1周内发热显著下降，甚至CRP在用甲氨蝶呤治疗1周后显着降低，没有发现任何不良反应 [<xref ref-type="bibr" rid="hanspub.31582-ref49">49</xref>] 。类似的报道后来很少见到 [<xref ref-type="bibr" rid="hanspub.31582-ref50">50</xref>] [<xref ref-type="bibr" rid="hanspub.31582-ref51">51</xref>] 。</p></sec></sec></sec><sec id="s5"><title>3. 国内KD临床治疗进展</title><sec id="s5_1"><title>3.1. 专业组织推荐方案</title><p>2007年11月，《中华儿科杂志》编辑委员会、中华医学会儿科学分会心血管学组、中华医学会儿科学分会免疫学组联合发布了《川崎病专题讨论会纪要》，其中对KD治疗形成了诸多共识 [<xref ref-type="bibr" rid="hanspub.31582-ref52">52</xref>] 。</p><sec id="s5_1_1"><title>3.1.1. KD急性期治疗</title><p>1) ASA。在综合国内外研究进展基础上，与会专家一致推荐ASA与IVIG联合使用，剂量为30~50 mg/(kg&#183;d)，ASA用药至热退48~72 h改为小剂量3~5 mg/(kg&#183;d)，维持6~8周，有冠脉受累者，按受累程度决定疗程；2) IVIG。尽管专家对国外推荐的起病10 d内单剂次IVIG (2 g/kg)联合ASA疗法并无异议，但考虑到我国居民实际承受能力，专家就IVIG使用方法争议较大，一直否决了400 mg/(kg&#183;d)连用5 d的治疗方案，但单剂次1 g/kg治疗方案是否完全放弃尚未达成一致；3) CCs。考虑到当时相关研究资料的病例数偏少，剂型、疗程及用药前冠状动脉损害情况各异，专家一致认为CCs暂不应作为KD常规治疗的一线药物 [<xref ref-type="bibr" rid="hanspub.31582-ref52">52</xref>] 。</p></sec><sec id="s5_1_2"><title>3.1.2. IVIG无反应型KD治疗</title><p>IVIG治疗后36 h发热不退或给药后2~7 d症状再现，除外继发感染情况，可判断为IVIG无反应型KD [<xref ref-type="bibr" rid="hanspub.31582-ref52">52</xref>] 。关于IVIG无反应型KD治疗，专家意见为：1) IVIG不敏感者可重复使用IVIG (2 g/kg)治疗1次；2) 如仍发热不退，应采用CCs治疗；3) 第2剂次IVIG治疗无效者，建议采用甲泼尼龙[2 mg/(kg&#183;d)]静脉滴注或推注，分2~3次给药，连续3 d，继以口服泼尼松治疗，逐渐减量，疗程6周；4) 如果2 mg/(kg&#183;d)甲泼尼龙无效，可考虑甲泼尼龙30 mg/kg每日一次静脉滴注，1~3 d后减量停药；5) 考虑到大剂量CCs冲击治疗可能明显加重高凝状态，有冠脉病变者尤易形成血栓，用药过程中应静脉使用肝素抗凝，有CAA者最好用小剂量静脉制剂或口服泼尼松治疗；6) 其它治疗方法尚待进一步证实 [<xref ref-type="bibr" rid="hanspub.31582-ref52">52</xref>] 。</p></sec></sec><sec id="s5_2"><title>3.2. 国内学者KD临床治疗研究进展</title><p>近年来，我国学者在KD临床治疗方面进行了诸多研究，但多为国外已有研究结果的临床再应用及效果评价 [<xref ref-type="bibr" rid="hanspub.31582-ref53">53</xref>] [<xref ref-type="bibr" rid="hanspub.31582-ref54">54</xref>] [<xref ref-type="bibr" rid="hanspub.31582-ref55">55</xref>] 。值得注意的是，一项纳入了5983例KD患儿的“川崎病接受首次静脉使用免疫球蛋白标准量后病情反应情况与治疗前实验室指标相关性的Meta分析”结果表明，IVIG无反应型KD可能与低Hb、低ALB、低血钠和高CRP、高ALT、高AST有关 [<xref ref-type="bibr" rid="hanspub.31582-ref56">56</xref>] 。目前，国内有关中医药治疗KD报道不少 [<xref ref-type="bibr" rid="hanspub.31582-ref57">57</xref>] ，也有中西医结合治疗KD的报道 [<xref ref-type="bibr" rid="hanspub.31582-ref58">58</xref>] 。介入治疗、手术治疗主要用于KD严重并发症患者 [<xref ref-type="bibr" rid="hanspub.31582-ref59">59</xref>] [<xref ref-type="bibr" rid="hanspub.31582-ref60">60</xref>] 。</p></sec></sec><sec id="s6"><title>4. 讨论</title><sec id="s6_1"><title>4.1. KD急性期治疗</title><p>目前，国内外对KD急性期的临床治疗方案基本形成共识。从疗效方面考虑，尽早使用高剂量(2 g/kg) IVIG治疗KD已成为国内外专家共识 [<xref ref-type="bibr" rid="hanspub.31582-ref2">2</xref>] [<xref ref-type="bibr" rid="hanspub.31582-ref52">52</xref>] ，尽管ASA使用风险被屡次报道，但ASA联合IVIG治疗急性期KD已成主流 [<xref ref-type="bibr" rid="hanspub.31582-ref2">2</xref>] [<xref ref-type="bibr" rid="hanspub.31582-ref24">24</xref>] [<xref ref-type="bibr" rid="hanspub.31582-ref52">52</xref>] ，分歧更多的是ASA使用剂量问题，相比而言，国内专家推荐的30~50 mg/kg/d的中等剂量更为稳妥，待发热症状消退后可改为小剂量维持治疗。同时，综合国内外现有研究结果，在KD急性期应优先使用IVIG联合ASA治疗方案，如果治疗有效，应暂不考虑使用CCs。</p></sec><sec id="s6_2"><title>4.2. 耐药性KD治疗</title><p>目前，国内外有关耐药性KD定义基本一致 [<xref ref-type="bibr" rid="hanspub.31582-ref2">2</xref>] [<xref ref-type="bibr" rid="hanspub.31582-ref52">52</xref>] ，但在IVIG或联合ASA治疗KD效果不佳时，如何进一步治疗国内外意见尚存分歧。1) CCs何时使用问题。有建议在第1次IVIG治疗不能降低炎症的情况下使用CCs [<xref ref-type="bibr" rid="hanspub.31582-ref24">24</xref>] ，有建议仅在2次以上输注IVIG无反应的病例中使用CCs [<xref ref-type="bibr" rid="hanspub.31582-ref24">24</xref>] ，而美国AHA和我国专家建议对第2剂次IVIG治疗无效者使用CCs [<xref ref-type="bibr" rid="hanspub.31582-ref2">2</xref>] [<xref ref-type="bibr" rid="hanspub.31582-ref52">52</xref>] 。综合国内外现有研究结果及专家意见，我们建议：一般情况下，对第2剂次IVIG治疗无效者可使用CCs，但如果考虑到患儿家属实际经济承受能力，在知情同意情况下，在第1剂次高剂量(2 g/kg) IVIG治疗无效时，可考虑第2剂次小剂量(1 g/kg) IVIC联合CCs治疗。同时，应严密监测心率、血糖等相关指标。2) 如果耐药性KD经使用CCs治疗仍无效时怎么办？关于这个问题，国外有多种治疗方法可供选择，包括：TNF-α抑制剂、PE、环孢菌素等 [<xref ref-type="bibr" rid="hanspub.31582-ref31">31</xref>] [<xref ref-type="bibr" rid="hanspub.31582-ref36">36</xref>] [<xref ref-type="bibr" rid="hanspub.31582-ref41">41</xref>] 。相比而言，我国专家对上述治疗方法持谨慎态度 [<xref ref-type="bibr" rid="hanspub.31582-ref52">52</xref>] 。然而，我国专家的上述认识形成于2007年，当时所参考的国内外文献基本为2005年以前的文献 [<xref ref-type="bibr" rid="hanspub.31582-ref52">52</xref>] 。时至今日10多年过去了，期间国内外有关耐药性KD治疗与研究已今非昔比。1) 目前，TNF-α拮抗剂中单克隆抗体(英夫利昔单抗或阿达木单抗)已应用于临床治疗，许多研究已证实其可用于治疗难治性KD [<xref ref-type="bibr" rid="hanspub.31582-ref31">31</xref>] ，国内也已有这方面报道 [<xref ref-type="bibr" rid="hanspub.31582-ref61">61</xref>] 。国内应积极借鉴国外经验，在IVIG难治患者方面进行探索。2) 国外研究已证实PE治疗耐药性KD效果显著 [<xref ref-type="bibr" rid="hanspub.31582-ref36">36</xref>] [<xref ref-type="bibr" rid="hanspub.31582-ref37">37</xref>] [<xref ref-type="bibr" rid="hanspub.31582-ref38">38</xref>] ，国内也已有这方面报道 [<xref ref-type="bibr" rid="hanspub.31582-ref62">62</xref>] ，国内学者应综合分析KD患儿情况，在第2次静脉注射IVIG治疗无效后，可尝试PE方法治疗，以积累国内有关方面经验。3) 尽管国外已有环孢菌素治疗耐药性KD的正面报道 [<xref ref-type="bibr" rid="hanspub.31582-ref41">41</xref>] ，但国外进一步研究仍在进行中 [<xref ref-type="bibr" rid="hanspub.31582-ref42">42</xref>] ，国内学者应关注国外特别是日本在环孢菌素治疗难治性KD方面进展，以便及时汲取经验或教训。4) 国外有关环磷酰胺、甲氨蝶呤治疗难治性KD的相关报道病例数相对较少 [<xref ref-type="bibr" rid="hanspub.31582-ref45">45</xref>] [<xref ref-type="bibr" rid="hanspub.31582-ref48">48</xref>] [<xref ref-type="bibr" rid="hanspub.31582-ref49">49</xref>] ，国内可暂不予关注。</p></sec><sec id="s6_3"><title>4.3. 其他值得关注的问题</title><p>1) 研究设计应严谨。目前，国内外有关KD临床治疗的研究对象或病例数相对较少，特别在开展随机对照试验研究时，一定要充分考虑治疗组和对照组的随机性且具有较强的可比性，否则可能会因混杂因素的影响，研究得出与事实不相符的结论。2) KD患者耐药的原因值得深入研究。遇到耐药性KD时，不仅应考虑其他治疗方法，以期尽早治愈患者，也应思考与研究为什么这些患者会出现耐药。如果耐药的真正原因找到了，针对这些原因采取相应治疗措施，有可能从根本上破解KD耐药的难题。已有研究初步表明，IVIG无反应型KD可能与低Hb、低ALB、低血钠和高CRP、高ALT、高AST有关 [<xref ref-type="bibr" rid="hanspub.31582-ref56">56</xref>] ，值得进一步研究。3) 祖国医学的潜力值得挖掘。中医药治疗KD、中西医结合治疗KD值得我国学者深入研究。4) 未来，我国应在积极学习借鉴国外先进经验的基础上，加快建立健全国内多中心、多学科、大样本随机对照试验研究，以可信度更高的数据支撑国内KD临床治疗与研究工作跟上国际步伐。</p></sec></sec><sec id="s7"><title>文章引用</title><p>吕菊红,马红茹,邓 峰. 国内外川崎病临床治疗进展Progress in Clinical Treatment of Kawasaki Disease at Home and Abroad[J]. 临床医学进展, 2019, 09(08): 889-897. https://doi.org/10.12677/ACM.2019.98137</p></sec><sec id="s8"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.31582-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Kawasaki, T. (2006) Kawasaki Disease. Proceedings of the Japan Academy, Ser. B, Physical and Biological Science, 82, 59-71. &lt;br&gt;https://doi.org/10.2183/pjab.82.59</mixed-citation></ref><ref id="hanspub.31582-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">McCrindle, B.W., Rowley, A.H., Newburger, J.W., et al. (2017) Diagnosis, Treatment, and Long-Term Management of Kawasaki Disease: A Scientific Statement for Health Professionals from the American Heart Association. Circulation, 135, e927-e999. &lt;br&gt;https://doi.org/10.1161/CIR.0000000000000484</mixed-citation></ref><ref id="hanspub.31582-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">杜忠东, 陈笑征. 川崎病流行病学研究进展[J]. 中国实用儿科杂志, 2017, 32(8): 565-569.</mixed-citation></ref><ref id="hanspub.31582-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">张新艳, 杨婷婷, 何婷, 等. 2012至2016年单中心川崎病流行病学及临床特征研究[J]. 中国循证儿科杂志, 2018, 13(6): 427-432.</mixed-citation></ref><ref id="hanspub.31582-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Pilania, R.K., Bhattarai, D. and Singh, S. (2018) Controversies in Diagnosis and Management of Kawasaki Disease. World Journal of Clinical Pediatrics, 7, 27-35. &lt;br&gt;https://doi.org/10.5409/wjcp.v7.i1.27</mixed-citation></ref><ref id="hanspub.31582-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Lo, M.S. and Newburger, J.W. (2018) Role of Intravenous Immuno-globulin in the Treatment of Kawasaki Disease. International Journal of Rheumatic Diseases, 21, 64-69. &lt;br&gt;https://doi.org/10.1111/1756-185X.13220</mixed-citation></ref><ref id="hanspub.31582-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Kuo, H.-C., Hsu, Y.-W., Wc, M.-S., et al. (2016) Intravenous Immunoglobulin, Pharmacogenomics, and Kawasaki Disease. Journal of Microbiology, Immunology and Infection, 49, 1-7. &lt;br&gt;https://doi.org/10.1016/j.jmii.2014.11.001</mixed-citation></ref><ref id="hanspub.31582-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Kuo, H.C., Yang, K.D., Chang, W.C., et al. (2012) Kawasaki Disease: An Update on Diagnosis and Treatment. Pediatrics &amp; Neonatology, 53, 4-11. &lt;br&gt;https://doi.org/10.1016/j.pedneo.2011.11.003</mixed-citation></ref><ref id="hanspub.31582-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Muta, H., Ishii, M., Yashiro, M., et al. (2012) Late Intravenous Immunoglobulin Treatment in Patients with Kawasaki Disease. Pediatrics, 129, e291-297. &lt;br&gt;https://doi.org/10.1542/peds.2011-1704</mixed-citation></ref><ref id="hanspub.31582-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Muta, H., Ishii, M., Egami, K., et al. (2004) Early Intravenous Gammaglobulin Treatment for Kawasaki Disease: The Nationwide Surveys in Japan. The Journal of Pediatrics, 144, 496-499. &lt;br&gt;https://doi.org/10.1016/j.jpeds.2003.12.033</mixed-citation></ref><ref id="hanspub.31582-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Rowley, A.H. (2015) The Complexities of the Diagnosis and Management of Kawasaki Disease. Infectious Disease Clinics of North America, 29, 525-537. &lt;br&gt;https://doi.org/10.1016/j.idc.2015.05.006</mixed-citation></ref><ref id="hanspub.31582-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Fujimaru, T., Ito, S., Masuda, H., et al. (2014) Decreased Levels of Inflammatory Cytokines in Immunoglobulin-Resistant Kawasaki Disease after Plasma Exchange. Cytokine, 70, 156-160.  
&lt;br&gt;https://doi.org/10.1016/j.cyto.2014.07.003</mixed-citation></ref><ref id="hanspub.31582-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Bayers, S., Shulman, S.T. and Paller, A.S. (2013) Kawasaki Dis-ease: Part II. Complications and Treatment. Journal of the American Academy of Dermatology, 69, 513e1-8. &lt;br&gt;https://doi.org/10.1016/j.jaad.2013.06.040</mixed-citation></ref><ref id="hanspub.31582-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Rahbarimanesh, A., Taghavi-Goodarzi, M., Mohammadinejad, P., et al. (2014) Comparison of High-Dose versus Low-Dose Aspirin in the Management of Kawasaki Disease. Indian Journal of Pediatrics, 81, 1403.  
&lt;br&gt;https://doi.org/10.1007/s12098-014-1437-0</mixed-citation></ref><ref id="hanspub.31582-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">Dallaire, F., Fortier-Morissette, Z., Blais, S., et al. (2017) Aspirin Dose and Prevention of Coronary Abnormalities in Kawasaki Disease. Pediatrics, 139, e20170098. &lt;br&gt;https://doi.org/10.1542/peds.2017-0098</mixed-citation></ref><ref id="hanspub.31582-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">Ho, L.G.Y. and Curtis, N. (2017) What Dose of Aspirin Should Be Used in the Initial Treatment of Kawasaki Disease. Archives of Disease in Childhood, 102, 1180-1182. &lt;br&gt;https://doi.org/10.1136/archdischild-2017-313538</mixed-citation></ref><ref id="hanspub.31582-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">Zhu, F.H. and Ang, J.Y. (2016) The Clinical Diagnosis and Management of Kawasaki Disease: A Review and Update. Current Infectious Disease Reports, 18, 32. &lt;br&gt;https://doi.org/10.1007/s11908-016-0538-5</mixed-citation></ref><ref id="hanspub.31582-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">Kato, H., Koike, S. and Yokoyama, T. (1979) Kawasaki Disease: Effect of Treatment on Coronary Artery Involvement. Pediatrics, 63, 175-179.</mixed-citation></ref><ref id="hanspub.31582-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">Eleftheriou, D., Levin, M., Shin-gadia, D., et al. (2014) Management of Kawasaki Disease. Archives of Disease in Childhood, 99, 74-83. &lt;br&gt;https://doi.org/10.1136/archdischild-2012-302841</mixed-citation></ref><ref id="hanspub.31582-ref20"><label>20</label><mixed-citation publication-type="other" xlink:type="simple">Kobayashi, T., Saji, T., Otani, T., et al. (2012) Efficacy of Immunoglobulin plus Prednisolone for Prevention of Coronary Artery Abnormalities in Severe Kawasaki Disease: Raise Study, a Randomised, Open-Label, Blinded-Endpoints Trial. The Lancet, 379, 1613-1620. &lt;br&gt;https://doi.org/10.1016/S0140-6736(11)61930-2</mixed-citation></ref><ref id="hanspub.31582-ref21"><label>21</label><mixed-citation publication-type="other" xlink:type="simple">Singh, S., Sharma, A. and Jiao, F. (2016) Kawasaki Disease: Issues in Diagnosis and Treatment—A Developing Country Perspective. Indian Journal of Pediatrics, 83, 140-145. &lt;br&gt;https://doi.org/10.1007/s12098-015-1890-4</mixed-citation></ref><ref id="hanspub.31582-ref22"><label>22</label><mixed-citation publication-type="other" xlink:type="simple">Singh, S., Newburger, J.W., Kuijpers, T., et al. (2015) Manage-ment of Kawasaki Disease in Resource-Limited Settings. The Pediatric Infectious Disease Journal, 34, 94-96. &lt;br&gt;https://doi.org/10.1097/INF.0000000000000600</mixed-citation></ref><ref id="hanspub.31582-ref23"><label>23</label><mixed-citation publication-type="other" xlink:type="simple">Adachi, S., Sakaguchi, H., Kuwahara, T., et al. (2010) High Regression Rate of Coronary Anuerysms Developed in Patients with Immune Globulin Resistant Kawasaki Disease Treated with Steroid Pulse Therapy. The Tohoku Journal of Experimental Medicine, 220, 285-290. &lt;br&gt;https://doi.org/10.1620/tjem.220.285</mixed-citation></ref><ref id="hanspub.31582-ref24"><label>24</label><mixed-citation publication-type="other" xlink:type="simple">Saneeymehri, S., Baker, K. and So, T.Y. (2015) Overview of Pharma-cological Treatment Options for Pediatric Patients with Refractory Kwasaki Disease. The Journal of Pediatric Phar-macology and Therapeutics, 20, 163-177.</mixed-citation></ref><ref id="hanspub.31582-ref25"><label>25</label><mixed-citation publication-type="other" xlink:type="simple">Ogata, S., Ogihara, Y., Honda, T., et al. (2012) Corticosteroid Pulse Combination Therapy for Refractory Kawasaki Disease: A Randomized Trial. Pediatrics, 129, e17-e23. &lt;br&gt;https://doi.org/10.1542/peds.2011-0148</mixed-citation></ref><ref id="hanspub.31582-ref26"><label>26</label><mixed-citation publication-type="other" xlink:type="simple">Chen, S., Dong, Y., Yin, Y., et al. (2013) Intravenous Immuno-globulin plus Corticosteroid to Prevent Coronary Artery Abnormalities in Kawasaki Disease: A Meta-Analysis. Heart, 99, 76-82. &lt;br&gt;https://doi.org/10.1136/heartjnl-2012-302126</mixed-citation></ref><ref id="hanspub.31582-ref27"><label>27</label><mixed-citation publication-type="other" xlink:type="simple">Weng, K.P., Ou, S.F., Lin, C.C., et al. (2011) Recent Advances in the Treatment of Kawasaki Disease. Journal of the Chinese Medical Association, 74, 481-484. &lt;br&gt;https://doi.org/10.1016/j.jcma.2011.09.001</mixed-citation></ref><ref id="hanspub.31582-ref28"><label>28</label><mixed-citation publication-type="other" xlink:type="simple">Yu, J.J. (2015) Use of Corticosteroids during Acute Phase of Kawasaki Disease. World Journal of Clinical Pediatrics, 4, 135. &lt;br&gt;https://doi.org/10.5409/wjcp.v4.i4.135</mixed-citation></ref><ref id="hanspub.31582-ref29"><label>29</label><mixed-citation publication-type="other" xlink:type="simple">Lim, Y.J. and Jung, J.W. (2014) Clinical Outcomes of Initial Dexamethasone Treatment Combined with a Single High Dose of Intravenous Immunoglobulin for Primary Treatment of Kawasaki Disease. Yonsei Medical Journal, 55, 1260-1266. &lt;br&gt;https://doi.org/10.3349/ymj.2014.55.5.1260</mixed-citation></ref><ref id="hanspub.31582-ref30"><label>30</label><mixed-citation publication-type="other" xlink:type="simple">Portman, M.A., Olson, A., Soriano, B., et al. (2011) Etanercept as Adjunctive Treatment for Acute Kawasaki Disease: Study Design and Rationale. American Heart Journal, 161, 494-499. &lt;br&gt;https://doi.org/10.1016/j.ahj.2010.12.003</mixed-citation></ref><ref id="hanspub.31582-ref31"><label>31</label><mixed-citation publication-type="other" xlink:type="simple">Agarwal, S. and Devendra, K. (2017) Kawasaki Disease: Etiopathogenesis and Novel Treatment Strategies. Expert Review of Clinical Immunology, 13, 247-258. &lt;br&gt;https://doi.org/10.1080/1744666X.2017.1232165</mixed-citation></ref><ref id="hanspub.31582-ref32"><label>32</label><mixed-citation publication-type="other" xlink:type="simple">Mori, M., Imagawa, T., Hara, R., et al. (2012) Efficacy and Limitation of Infliximab Treatment for Children with Kawasaki Disease Intractable to Intravenous Immunoglobulin Therapy: Report of an Open-Label Case Series. The Journal of Rheumatology, 39, 864-867. &lt;br&gt;https://doi.org/10.3899/jrheum.110877</mixed-citation></ref><ref id="hanspub.31582-ref33"><label>33</label><mixed-citation publication-type="other" xlink:type="simple">Tremoulet, A.H., Jain, S., Jaggi, P., et al. (2014) Infliximab for In-tensification of Primary Therapy for Kawasaki Disease: A Phase 3 Randomised, Double-Blind, Placebo-Controlled Trial. The Lancet, 383, 1731-1738.  
&lt;br&gt;https://doi.org/10.1016/S0140-6736(13)62298-9</mixed-citation></ref><ref id="hanspub.31582-ref34"><label>34</label><mixed-citation publication-type="other" xlink:type="simple">Williams, R.V., Wilke, V.M., Tani, L.Y., et al. (2002) Does Abciximab Enhance Regression of Coronary Aneurysms Resulting from Kawasaki Disease. Pediatrics, 109, E4. &lt;br&gt;https://doi.org/10.1542/peds.109.1.e4</mixed-citation></ref><ref id="hanspub.31582-ref35"><label>35</label><mixed-citation publication-type="other" xlink:type="simple">Choueiter, N.F., Olson, A.K., Shen, D.D., et al. (2010) A Prospective Open Label Trial of Etanercept as Adjunctive Therapy for Kawasaki Disease. The Journal of Pediatrics, 157, 960-966. &lt;br&gt;https://doi.org/10.1016/j.jpeds.2010.06.014</mixed-citation></ref><ref id="hanspub.31582-ref36"><label>36</label><mixed-citation publication-type="other" xlink:type="simple">Mori, M., Imagawa, T., Katakura, S., et al. (2004) Efficacy of Plasma Exchange Therapy for Kawasaki Disease Intractable to Intravenous Gamma-Globulin. Modern Rheumatology, 14, 43-47. &lt;br&gt;https://doi.org/10.3109/s10165-003-0264-3</mixed-citation></ref><ref id="hanspub.31582-ref37"><label>37</label><mixed-citation publication-type="other" xlink:type="simple">Matsui, M., Okuma, Y., Yamanaka, J., et al. (2015) Kawasaki Disease Refractory to Standard Treatments That Responds to a Combination of Pulsed Methylprednisolone and Plasma Exchange: Cytokine Profiling and Literature Review. Cytokine, 74, 339-342. &lt;br&gt;https://doi.org/10.1016/j.cyto.2015.02.014</mixed-citation></ref><ref id="hanspub.31582-ref38"><label>38</label><mixed-citation publication-type="other" xlink:type="simple">Sonoda, K., Mori, M., Hokosaki, T., et al. (2014) Infliximab plus Plasma Exchange Rescue Therapy in Kawasaki Disease. The Journal of Pediatrics, 164, 1128-1132. &lt;br&gt;https://doi.org/10.1016/j.jpeds.2014.01.020</mixed-citation></ref><ref id="hanspub.31582-ref39"><label>39</label><mixed-citation publication-type="other" xlink:type="simple">Tremoulet, A.H., Pancoast, P., Franco, A., et al. (2012) Cal-cineurin Inhibitor Treatment of Intravenous Immunoglubulin Resistant Kawasaki Disease. The Journal of Pediatrics, 161, 506-512. &lt;br&gt;https://doi.org/10.1016/j.jpeds.2012.02.048</mixed-citation></ref><ref id="hanspub.31582-ref40"><label>40</label><mixed-citation publication-type="other" xlink:type="simple">Kuijpers, T.W., Biezeveld, M., Achterhuis, A., et al. (2003) Longstanding Obliterative Panarteritis in Kawasaki Disease: Lack of Cyclosporin A Effect. Pediatrics, 112, 986-992. &lt;br&gt;https://doi.org/10.1542/peds.112.4.986</mixed-citation></ref><ref id="hanspub.31582-ref41"><label>41</label><mixed-citation publication-type="other" xlink:type="simple">Suzuki, H., Terai, M., Hamada, H., et al. (2011) Cyclosporin A Treatment for Kawasaki Disease Refractory to Initial and Additional Intravenous Immunoglobulin. The Pediatric Infectious Disease Journal, 30, 871-876.  
&lt;br&gt;https://doi.org/10.1097/INF.0b013e318220c3cf</mixed-citation></ref><ref id="hanspub.31582-ref42"><label>42</label><mixed-citation publication-type="other" xlink:type="simple">Aoyagi, R., Hamada, H., Sato, Y., et al. (2015) Study Pro-tocol for a Phase III Multicentre, Randomised, Open-Label, Blinded-End Point Trial to Evaluate the Efficacy and Safety of Immunoglobulin plus Cyclosporin A in Patients with Severe Kawasaki Disease (KAICA Trial). BMJ Open, 5, e009562. &lt;br&gt;https://doi.org/10.1136/bmjopen-2015-009562</mixed-citation></ref><ref id="hanspub.31582-ref43"><label>43</label><mixed-citation publication-type="other" xlink:type="simple">Rodrigues-Diez, R., González-Guerrero, C., Ocaña-Salceda, C., et al. (2016) Calcineurin Inhibitors Cyclosporine A and Tacrolimus Induce Vascular Inflammation and Endothelial Activation through TLR4 Signaling. Scientific Reports, 6, Article No. 27915. &lt;br&gt;https://doi.org/10.1038/srep27915</mixed-citation></ref><ref id="hanspub.31582-ref44"><label>44</label><mixed-citation publication-type="other" xlink:type="simple">Al-Homsi, A.S., Roy, T.S., Cole, K., et al. (2015) Post-Transplant High-Dose Cyclophosphamide for the Prevention of Graft-versus-Host Disease. Biology of Blood and Marrow Trans-plantation, 21, 604-611.  
&lt;br&gt;https://doi.org/10.1016/j.bbmt.2014.08.014</mixed-citation></ref><ref id="hanspub.31582-ref45"><label>45</label><mixed-citation publication-type="other" xlink:type="simple">Falcini, F. (2006) Kawasaki Disease. Current Opinion in Rheu-matology, 18, 33-38.  
&lt;br&gt;https://doi.org/10.1097/01.bor.0000197998.50450.f6</mixed-citation></ref><ref id="hanspub.31582-ref46"><label>46</label><mixed-citation publication-type="other" xlink:type="simple">Wong, P.T. and Choi, S.K. (2015) Mechanisms and Implications of Dual-Acting Methotrexate in Folate-Targeted Nanotherapeutic Delivery. International Journal of Mo-lecular Sciences, 16, 1772-1790.  
&lt;br&gt;https://doi.org/10.3390/ijms16011772</mixed-citation></ref><ref id="hanspub.31582-ref47"><label>47</label><mixed-citation publication-type="other" xlink:type="simple">Shulman, S.T. (1988) Management of Kawasaki Disease. The Journal of Pediatrics, 113, 1116-1117.  
&lt;br&gt;https://doi.org/10.1016/S0022-3476(88)80596-1</mixed-citation></ref><ref id="hanspub.31582-ref48"><label>48</label><mixed-citation publication-type="other" xlink:type="simple">Lee, M.S., An, S.Y., Jang, G.C., et al. (2002) A Case of In-travenous Immunoglobulin Resistant Kawasaki Disease Treated with Methotrexate. Yonsei Medical Journal, 43, 527-532. &lt;br&gt;https://doi.org/10.3349/ymj.2002.43.4.527</mixed-citation></ref><ref id="hanspub.31582-ref49"><label>49</label><mixed-citation publication-type="other" xlink:type="simple">Lee, T.J., Kim, K.H., Chun, J.K., et al. (2008) Low-Dose Methotrexate Therapy for Intravenous Immunoglobulin-Resistant Kawasaki Disease. Yonsei Medical Journal, 49, 714-718. &lt;br&gt;https://doi.org/10.3349/ymj.2008.49.5.714</mixed-citation></ref><ref id="hanspub.31582-ref50"><label>50</label><mixed-citation publication-type="other" xlink:type="simple">Kim, N.Y., Choi, D.Y., Jung, M.J., et al. (2008) A Case of Refractory Kawasaki Disease Complicated by Peripheral Ischemia. Pediatric Cardiology, 29, 1110-1114. &lt;br&gt;https://doi.org/10.1007/s00246-008-9221-4</mixed-citation></ref><ref id="hanspub.31582-ref51"><label>51</label><mixed-citation publication-type="other" xlink:type="simple">Magalhães, C.M.R., Alves, N.R., Melo, A.V., et al. (2012) Cata-strophic Kawasaki Disease Unresponsive to IVIG in a 3-Month-Old Infant: A Diagnostic and Therapeutic Challenge. Pediatric Rheumatology Online Journal, 10, 28.  
&lt;br&gt;https://doi.org/10.1186/1546-0096-10-28</mixed-citation></ref><ref id="hanspub.31582-ref52"><label>52</label><mixed-citation publication-type="other" xlink:type="simple">《中华儿科杂志》编辑委员会, 中华医学会儿科学分会心血管学组, 中华医学会儿科学分会免疫学组. 川崎病专题讨论会纪要[J]. 中华儿科学杂志, 2007, 45(11): 826-830.</mixed-citation></ref><ref id="hanspub.31582-ref53"><label>53</label><mixed-citation publication-type="other" xlink:type="simple">梁亚晓, 梁艳萍. 不同剂量丙种球蛋白联合阿司匹林治疗川崎病的临床研究[J]. 泰山医学院学报, 2019, 40(1): 72-74.</mixed-citation></ref><ref id="hanspub.31582-ref54"><label>54</label><mixed-citation publication-type="other" xlink:type="simple">张艳红. 不同剂量的丙种免疫球蛋白治疗方案对川崎病患儿冠状动脉病变的影响观察[J]. 现代诊断与治疗, 2018, 29(1): 95-96.</mixed-citation></ref><ref id="hanspub.31582-ref55"><label>55</label><mixed-citation publication-type="other" xlink:type="simple">江佳峪, 赵世权, 高小平. 不同途径给予激素治疗丙种球蛋白无反应型川崎病临床观察[J]. 解放军医药杂志, 2019, 31(1): 63-66.</mixed-citation></ref><ref id="hanspub.31582-ref56"><label>56</label><mixed-citation publication-type="other" xlink:type="simple">刘卓勋, 温晓莹, 郑燕霞, 等. 川崎病接受首次静脉使用免疫球蛋白标准剂量后病情反应情况与治疗前实验室指标相关性的Meta分析[J]. 中国循证医学杂志, 2018, 18(4): 347-353.</mixed-citation></ref><ref id="hanspub.31582-ref57"><label>57</label><mixed-citation publication-type="other" xlink:type="simple">何炜星, 张涤. 张涤教授治疗川崎病经验拾萃[J]. 湖南中医药大学学报, 2019, 39(2): 218-221.</mixed-citation></ref><ref id="hanspub.31582-ref58"><label>58</label><mixed-citation publication-type="other" xlink:type="simple">安娜, 李晨, 段保湘, 等. 中西医结合治疗川崎病疗效评价[J]. 中华中医药学刊, 2017, 35(5): 1310-1312.</mixed-citation></ref><ref id="hanspub.31582-ref59"><label>59</label><mixed-citation publication-type="other" xlink:type="simple">李小青, 匡琳, 吴俊, 等. 川崎病治疗进展[J]. 现代临床医学, 2016, 42(5): 328-330.</mixed-citation></ref><ref id="hanspub.31582-ref60"><label>60</label><mixed-citation publication-type="other" xlink:type="simple">郭俊, 沈下贤, 张必利, 等. 介入治疗川崎病并发冠状动脉损害１例并文献回顾[J]. 第二军医大学学报, 2015, 36(11): 1275-1277.</mixed-citation></ref><ref id="hanspub.31582-ref61"><label>61</label><mixed-citation publication-type="other" xlink:type="simple">张鹏宇, 汤楚中, 潘绪, 等. 英夫利西单抗与 IVIG 治疗 IVIG 初治无效川崎病效果比较[J]. 中国医学前沿杂志(电子版), 2018, 10(5): 60-63.</mixed-citation></ref><ref id="hanspub.31582-ref62"><label>62</label><mixed-citation publication-type="other" xlink:type="simple">吴洁. 丙种球蛋白无反应型川崎病预测评分系统的验证及血浆置换治疗川崎病269例的系统评价[D]: [硕士学位论文]. 苏州: 苏州大学, 2018.</mixed-citation></ref></ref-list></back></article>